Literature DB >> 6199630

Substance P is markedly increased in plasma of patients with hepatic coma.

H Hörtnagl, E A Singer, K Lenz, G Kleinberger, H Lochs.   

Abstract

Substance P (determined as immunoreactive substance P [i-SP]), noradrenaline, and adrenaline were measured in plasma of 18 patients with hepatic coma (stage I-IV), 16 healthy controls, and 10 critically ill patients without evidence of hepatocellular disease. Plasma i-SP (119 +/- 13 fmol/ml) was significantly higher in patients with hepatic coma than in healthy controls (13 +/- 2 fmol/ml) or control patients (23 +/- 4 fmol/ml). Plasma i-SP rose in parallel with plasma noradrenaline and adrenaline. There was a significant direct correlation between plasma i-SP and noradrenaline. Increase in plasma i-SP and noradrenaline was associated with a decrease in systemic vascular resistance and an increase in cardiac index and was most pronounced in those patients who finally died in coma. Deterioration in the dying patients was accompanied by a further significant increase in plasma i-SP. Immunoreactivity was identified as authentic SP by high performance liquid chromatography in 3 representative patients. Accumulation of the vasodilating peptide SP in plasma of patients with hepatic coma may be important in the pathogenesis of the cardiovascular disturbances associated with this disease.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6199630     DOI: 10.1016/s0140-6736(84)92851-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  19 in total

1.  Pathogenesis of pulmonary arteriovenous malformations: role of hepatopulmonary interactions.

Authors:  J J Vettukattil
Journal:  Heart       Date:  2002-12       Impact factor: 5.994

Review 2.  Pathophysiology and epidemiology of portal hypertension.

Authors:  H Okumura; T Aramaki; Y Katsuta
Journal:  Drugs       Date:  1989       Impact factor: 9.546

3.  Beneficial effect of 8-ornithin vasopressin on renal dysfunction in decompensated cirrhosis.

Authors:  K Lenz; H Hörtnagl; W Druml; G Grimm; A Laggner; B Schneeweisz; G Kleinberger
Journal:  Gut       Date:  1989-01       Impact factor: 23.059

4.  Measurement of plasma-derived substance P: biological, methodological, and statistical considerations.

Authors:  Donald E Campbell; Nancy Raftery; Richard Tustin; Nancy B Tustin; Michelle L Desilvio; Avital Cnaan; Pyone Pyone Aye; Andrew A Lackner; Steven D Douglas
Journal:  Clin Vaccine Immunol       Date:  2006-09-13

5.  Portal hypertension in acute liver failure.

Authors:  M Navasa; J C Garcia-Pagán; J Bosch; J R Riera; R Bañares; A Mas; M Bruguera; J Rodés
Journal:  Gut       Date:  1992-07       Impact factor: 23.059

6.  Influence of the degree of liver failure on systemic and splanchnic haemodynamics and on response to propranolol in patients with cirrhosis.

Authors:  A Braillon; P Cales; D Valla; D Gaudy; P Geoffroy; D Lebrec
Journal:  Gut       Date:  1986-10       Impact factor: 23.059

Review 7.  Pathogenesis of hepatic encephalopathy.

Authors:  L Zieve
Journal:  Metab Brain Dis       Date:  1987-09       Impact factor: 3.584

8.  Effect of a somatostatin analogue (SMS 201-995) on hemodynamics and glucagon secretion in cirrhotic rats.

Authors:  N Hori; T Okanoue; Y Sawa; T Mori; K Kashima
Journal:  Gastroenterol Jpn       Date:  1993-04

9.  The actions of two sensory neuropeptides, substance P and calcitonin gene-related peptide, on the canine hepatic arterial and portal vascular beds.

Authors:  P G Withrington
Journal:  Br J Pharmacol       Date:  1992-10       Impact factor: 8.739

Review 10.  New clues to the pathophysiology of hepatorenal failure.

Authors:  F Lang; W Gerok; D Häussinger
Journal:  Clin Investig       Date:  1993-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.